Surgery of Primary Lung Carcinoid Tumors at Metastatic Stage: A National Study from the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN Network
Introduction: The outcome of the primary lung neuroendocrine tumors surgery at metastatic stage remains poorly characterized. Methods: We conducted a retrospective national study including patients with metastatic lung neuroendocrine tumors at diagnosis. We performed a safety study to evaluate major morbidity and mortality of surgical resection of the primary tumor, and compared data in operative and non-operative group. Results: A total of 155 patients were included, 41 in the operative group and 114 in the non-operative group. The median age was 64 years. Metastases were mainly located in the liver (74.2%) and the bone (49.7%). The primary end-point was met as the rate of major complications was 4.9% and there was no post-operative mortality. In the operative group 42.5% of patients had improvement of their pulmonary symptoms, versus only 14.4% in the non-operative group. The median overall survival was not reached in the operative group and 4.3 years (95%CI [3.5;4.9]) in the non-operative group (univariate analysis, HR=0.42 95%CI [0.23;0.77], p=0.002). After multivariate analysis, only an ECOG-PS ≥1 (versus 0, HR=2.44, 95%CI [1.46;4.07], p=0.001) and >1 metastatic site (versus 1; HR=1.83, 95%CI [1.06;3.16], p=0.030) remained significantly associated with overall survival. The resection of the primary tumor was not significantly associated with OS (HR=0.63, 95%CI [0.32;1.24], p=0.183). Conclusions: Surgery of the primary lung neuroendocrine tumors at metastatic stage is a safe option that should be considered in selected patients in order to improve symptoms, with a view to improve their quality of life. Larger studies are warranted to evaluate the impact of surgery on survival.